Laraway Financial Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$319K Sell
1,468
-299
-17% -$66.3K 0.22% 103
2025
Q4
$404K Sell
1,767
-5
-0.3% -$1.14K 0.26% 85
2025
Q3
$410K Hold
1,772
0.28% 83
2025
Q2
$329K Sell
1,772
-24
-1% -$4.46K 0.25% 93
2025
Q1
$376K Buy
1,796
+1
+0.1% +$194 0.3% 80
2024
Q4
$319K Hold
1,795
0.25% 91
2024
Q3
$355K Hold
1,795
0.28% 84
2024
Q2
$308K Buy
1,795
+1
+0.1% +$166 0.26% 85
2024
Q1
$327K Hold
1,794
0.29% 86
2023
Q4
$278K Buy
1,794
+1
+0.1% +$146 0.26% 91
2023
Q3
$267K Sell
1,793
-25
-1% -$3.67K 0.28% 85
2023
Q2
$245K Buy
1,818
+1
+0.1% +$147 0.24% 93
2023
Q1
$290K Hold
1,817
0.29% 89
2022
Q4
$294K Sell
1,817
-33
-2% -$5.06K 0.31% 89
2022
Q3
$248K Hold
1,850
0.28% 94
2022
Q2
$283K Sell
1,850
-50
-3% -$7.64K 0.3% 87
2022
Q1
$307K Buy
1,900
+50
+3% +$7.26K 0.28% 91
2021
Q4
$250K Buy
+1,850
New +$219K 0.22% 98

Other funds holding ABBV

Laraway Financial Advisors's ABBV Position: Q1 2026 in Review

Laraway Financial Advisors reduced its AbbVie (ABBV) stake by 17% in Q1 2026, selling an estimated $66.3K and leaving 1,468 shares worth $319K. The position accounts for 0.22% of the portfolio, ranked #103.

Laraway Financial Advisors first reported a position in ABBV in Q4 2021 and has held it in 18 quarters since. The position peaked at $410K in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Laraway Financial Advisors held 1,468 shares of AbbVie worth $319K as of Q1 2026.
  • Laraway Financial Advisors sold 299 AbbVie shares in Q1 2026, an estimated $66.3K.
  • AbbVie made up 0.22% of Laraway Financial Advisors's portfolio in Q1 2026, its #103 holding.
  • Laraway Financial Advisors first reported a position in AbbVie in Q4 2021 and has held it in 18 quarters since.
  • Laraway Financial Advisors's AbbVie position peaked at $410K in Q3 2025.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Laraway Financial Advisors's 13F filing for Q1 2026, filed 14 May 2026.